Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Phase 1 Completed 50 enrolled Novo Nordisk A/S

RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.

Timeline

Start: 2004-02
Primary completion: 2004-08
Completion: 2004-08

Publications

Results Hompesch M, Troupin B, Heise T, Elbroend B, Endahl L, Haahr H, Heinemann L. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006 Sep;8(5):568-73. doi: 10.1111/j.1463-1326.2006.00643.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin NPH	Protein / enzyme biologic	0.3 iu/kg	Subcutaneous
Subject	insulin NPH	Protein / enzyme biologic	0.6 iu/kg	Subcutaneous
Subject	insulin NPH	Protein / enzyme biologic	1.2 iu/kg	Subcutaneous
Subject	insulin detemir	Protein / enzyme biologic	0.3 iu/kg	Subcutaneous
Subject	insulin detemir	Protein / enzyme biologic	0.6 iu/kg	Subcutaneous
Subject	insulin detemir	Protein / enzyme biologic	1.2 iu/kg	Subcutaneous

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications